115 related articles for article (PubMed ID: 6870929)
1. Effect of 5-benzylacyclouridine, a potent inhibitor of uridine phosphorylase, on the metabolism of circulating uridine by the isolated rat liver.
Monks A; Ayers O; Cysyk RL
Biochem Pharmacol; 1983 Jul; 32(13):2003-9. PubMed ID: 6870929
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of nucleoside transport in murine lymphoma L5178Y cells and human erythrocytes by the uridine phosphorylase inhibitors 5-benzylacyclouridine and 5-benzyloxybenzylacyclouridine.
Lee KH; el Kouni MH; Chu HS; Cha S
Cancer Res; 1984 Sep; 44(9):3744-8. PubMed ID: 6744292
[TBL] [Abstract][Full Text] [Related]
3. Species-dependent differences in the biochemical effects and metabolism of 5-benzylacyclouridine.
Davis ST; Joyner SS; Chandrasurin P; Baccanari DP
Biochem Pharmacol; 1993 Jan; 45(1):173-81. PubMed ID: 8424810
[TBL] [Abstract][Full Text] [Related]
4. Tissue-specific expansion of uridine pools in mice. Effects of benzylacyclouridine, dipyridamole and exogenous uridine.
Darnowski JW; Handschumacher RE; Wiegand RA; Goulette FA; Calabresi P
Biochem Pharmacol; 1991 Jun; 41(12):2031-6. PubMed ID: 2039551
[TBL] [Abstract][Full Text] [Related]
5. Effects of 5-benzylacyclouridine, an inhibitor of uridine phosphorylase, on the pharmacokinetics of uridine in rhesus monkeys: implications for chemotherapy.
Sommadossi JP; Cretton EM; Kidd LB; McClure HM; Anderson DC; el Kouni MH
Cancer Chemother Pharmacol; 1995; 37(1-2):14-22. PubMed ID: 7497584
[TBL] [Abstract][Full Text] [Related]
6. Benzylacyclouridine. Pharmacokinetics, metabolism and biochemical effects in mice.
Darnowski JW; Handschumacher RE
Biochem Pharmacol; 1988 Jul; 37(13):2613-8. PubMed ID: 3390221
[TBL] [Abstract][Full Text] [Related]
7. Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine.
Martin DS; Stolfi RL; Sawyer RC
Cancer Chemother Pharmacol; 1989; 24(1):9-14. PubMed ID: 2720896
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor.
Pizzorno G; Yee L; Burtness BA; Marsh JC; Darnowski JW; Chu MY; Chu SH; Chu E; Leffert JJ; Handschumacher RE; Calabresi P
Clin Cancer Res; 1998 May; 4(5):1165-75. PubMed ID: 9607574
[TBL] [Abstract][Full Text] [Related]
9. Expression, characterization, and detection of human uridine phosphorylase and identification of variant uridine phosphorolytic activity in selected human tumors.
Liu M; Cao D; Russell R; Handschumacher RE; Pizzorno G
Cancer Res; 1998 Dec; 58(23):5418-24. PubMed ID: 9850074
[TBL] [Abstract][Full Text] [Related]
10. 5-benzylacyclouridine and 5-benzyloxybenzylacyclouridine, potent inhibitors of uridine phosphorylase.
Niedzwicki JG; Chu SH; el Kouni MH; Rowe EC; Cha S
Biochem Pharmacol; 1982 May; 31(10):1857-61. PubMed ID: 7104017
[TBL] [Abstract][Full Text] [Related]
11. Tissue-specific enhancement of uridine utilization and 5-fluorouracil therapy in mice by benzylacyclouridine.
Darnowski JW; Handschumacher RE
Cancer Res; 1985 Nov; 45(11 Pt 1):5364-8. PubMed ID: 4053009
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of uridine phosphorylase: synthesis and structure-activity relationships of aryl-substituted 5-benzyluracils and 1-[(2-hydroxyethoxy)methyl]-5-benzyluracils.
Orr GF; Musso DL; Boswell GE; Kelley JL; Joyner SS; Davis ST; Baccanari DP
J Med Chem; 1995 Sep; 38(19):3850-6. PubMed ID: 7562916
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of uridine phosphorylase. Synthesis and structure-activity relationships of aryl-substituted 1-((2-hydroxyethoxy)methyl)-5-(3-phenoxybenzyl)uracil.
Orr GF; Musso DL; Kelley JL; Joyner SS; Davis ST; Baccanari DP
J Med Chem; 1997 Apr; 40(8):1179-85. PubMed ID: 9111291
[TBL] [Abstract][Full Text] [Related]
14. 19F NMR monitoring of in vivo tumor metabolism after biochemical modulation of 5-fluorouracil by the uridine phosphorylase inhibitor 5-benzylacyclouridine.
Holland SK; Bergman AM; Zhao Y; Adams ER; Pizzorno G
Magn Reson Med; 1997 Dec; 38(6):907-16. PubMed ID: 9402191
[TBL] [Abstract][Full Text] [Related]
15. Potentiation of 5-fluoro-2'-deoxyuridine antineoplastic activity by the uridine phosphorylase inhibitors benzylacyclouridine and benzyloxybenzylacyclouridine.
Chu MY; Naguib FN; Iltzsch MH; el Kouni MH; Chu SH; Cha S; Calabresi P
Cancer Res; 1984 May; 44(5):1852-6. PubMed ID: 6231986
[TBL] [Abstract][Full Text] [Related]
16. Inhibitor properties of some 5-substituted uracil acyclonucleosides, and 2,2'-anhydrouridines versus uridine phosphorylase from E. coli and mammalian sources.
Drabikowska AK; Lissowska L; Veres Z; Shugar D
Biochem Pharmacol; 1987 Dec; 36(23):4125-8. PubMed ID: 3318842
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of uridine phosphorylase from Escherichia coli by benzylacyclouridines.
Park KS; el Kouni MH; Krenitsky TA; Chu SH; Cha S
Biochem Pharmacol; 1986 Nov; 35(21):3853-5. PubMed ID: 3535805
[TBL] [Abstract][Full Text] [Related]
18. Uridine-induced hypothermia in mice and rats in relation to plasma and tissue levels of uridine and its metabolites.
Peters GJ; van Groeningen CJ; Laurensse EJ; Lankelma J; Leyva A; Pinedo HM
Cancer Chemother Pharmacol; 1987; 20(2):101-8. PubMed ID: 3664929
[TBL] [Abstract][Full Text] [Related]
19. Uridine regulation by the isolated rat liver: perfusion with an artificial oxygen carrier.
Monks A; Cysyk RL
Am J Physiol; 1982 May; 242(5):R465-70. PubMed ID: 7081472
[TBL] [Abstract][Full Text] [Related]
20. Activity and substrate specificity of pyrimidine phosphorylases and their role in fluoropyrimidine sensitivity in colon cancer cell lines.
Temmink OH; de Bruin M; Turksma AW; Cricca S; Laan AC; Peters GJ
Int J Biochem Cell Biol; 2007; 39(3):565-75. PubMed ID: 17098463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
